Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 18, 2024
Emerging Company Profile
Adaptin: Bispecifics hitchhike into the brain using edited T cells
Duke spinout has new method to get T cell engagers across the blood-brain barrier
BioCentury | Nov 11, 2020
Emerging Company Profile
CatalYm: opening up tumors to immune cells
Emerging Company Profile: German start-up targets GDF15’s immunosuppressant function to enable immune cell infiltration to tumors
BioCentury | Aug 28, 2020
Deals
BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration
JLABS funneling start-up innovation to BARDA via Blue Knight initiative
BioCentury | Apr 16, 2015
Product R&D
Antagonizing psoriasis
AnaptysBio is developing an IL-36R antagonist for orphan psoriasis indication
BioCentury | Apr 1, 2013
Finance
Dry eye payday
Competitive bidding for dry eye play SARcode yields payday for VCs
BioCentury | Apr 1, 2013
Strategy
Shire sees opportunity
Incoming Shire CEO outlines ophthalmics strategy after SARcode, Premacure deals
Items per page:
1 - 10 of 28